B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Drug Profile

B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Alternative Names: CIT; Combination Immunogene Therapy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Radient Pharmaceuticals Corporation
  • Class Cancer vaccines; Cytokine genes; Gene therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Canada (Parenteral, Injection)
  • 07 Dec 2010 Radient Pharmaceuticals forms new subsidiary NuVax Therapeutics, which will further develop this programme
  • 07 Apr 2010 Combination Immunogene Therapy is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top